Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy

Background Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality. Methods Here we describe the rationale and design of the Pha...

Full description

Saved in:

Bibliographic Details
Published in:	BMC neurology Vol. 17; no. 1; pp. 181 - 12
Main Authors:	Adams, David, Suhr, Ole B., Dyck, Peter J., Litchy, William J., Leahy, Raina G., Chen, Jihong, Gollob, Jared, Coelho, Teresa
Format:	Journal Article
Language:	English
Published:	London BioMed Central 11.09.2017 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Adolescent Adult Aged Aged, 80 and over Amyloidosis Amyloidosis - drug therapy APOLLO Autonomic nervous system Body mass Body Mass Index Clinical trials Diabetes Diabetes mellitus Diabetic Neuropathies - drug therapy Diabetic neuropathy Double-Blind Method Drug therapy hATTR amyloidosis Heart diseases Humans Innervation Intravenous administration Medicine Medicine & Public Health Methods Middle Aged mNIS+7 Morbidity Mutation Nerve conduction Neural Conduction Neurochemistry Neurology Neuromuscular disorders and peripheral neurology Neurosurgery Nutritional status Patients Patisiran Polyneuropathies - drug therapy Polyneuropathy Proteins Quality of Life Reflexes RNA interference RNA, Small Interfering - therapeutic use RNA-mediated interference Study Protocol Surveys and Questionnaires Young Adult β-Amyloid RNA interference hATTR amyloidosis APOLLO Patisiran mNIS+7 Polyneuropathy Methods
ISSN:	1471-2377, 1471-2377
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!